The term<unk> " or "follow-on<unk> " refers to a medication that is similar to a pre-existing<unk> , usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which<unk> s already exist. While pharmaceutical companies have justified the development of me-toos as offering incremental improvements in efficacy, side-effects, compliance and cost, critics have questioned the increasing marketing of me-toos, their absorption of research and development resources and their impact on the innovation of new treatments. In 1956, Louis S. Goodman, co‐editor of Goodman and Gilman, referred to “the problem of the introduction of ‘me too’<unk> s, that is,<unk> s without signal advantage of any sort”. However,<unk> s can be novel compounds themselves. They are commonly used and include several beta blockers, antidepressants and stomach acid reducing and cholesterol lowering<unk> s.
Me-too drug
Wonder Drug
Cold medicine
Proprietary drug
Hazardous drugs
Designer drug
Generic drug
Unused drug